News
Phase 1/2 trial expected to initiate in 2H 2025 in patients with BEST1 inherited retinal disease RESEARCH TRIANGLE PARK, N.C., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Opus Genetics (Nasdaq: IRD), a clinical ...
Anthropic’s Claude AI chatbot can now end conversations deemed “persistently harmful or abusive,” as spotted earlier by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback